期刊文献+

系统应用糖皮质激素治疗白癜风 被引量:2

Treatment of vitiligo with systemic corticosteroids
原文传递
导出
摘要 白癜风是一种常见的色素脱失性皮肤病,发病机制复杂且不完全清楚,治疗方式多样但疗效欠佳。研究表明,系统应用糖皮质激素通过其抗炎、免疫抑制等作用可以控制白癜风的进展、促进皮损复色,其治疗方法包括低剂量每日口服疗法、间歇疗法、冲击疗法,以及联合外用药、光疗、外科治疗等。系统应用糖皮质激素需根据白癜风类型、发展时期选择适宜的治疗方法,才能达到最佳疗效、减少不良反应。 Vitiligo is a kind of common skin disorder characterized by hypopigmentation. The pathogenesis of vitiligo is complex and not yet fully understood. Although many treatment options are available, therapeutic efficacy is unsatisfied. Studies have shown that systemic eortieosteroids can arrest the progression of vitiligo and lead to repigmentation through its anti-inflammatory and immunosuppressive effects. The modalities of cortieosteroid administration include low-dose daily use, intermittent therapy, pulse therapy, with or without combined topical therapy, phototherapy or surgical therapy. The selection of modalities should depend on the type and stage of vitiligo to achieve best therapeutic efficacy and minimize side effects.
出处 《国际皮肤性病学杂志》 2014年第2期83-86,共4页 International Journal of Dermatology and Venereology
关键词 白癜风 糖皮质激素类 治疗结果 Vitiligo Glueoeortieoids Treatment outcome
  • 相关文献

参考文献3

二级参考文献103

  • 1林挺,杨慧兰,刘仲荣,李雪梅,廖春.308nm准分子激光联合卡泊三醇软膏治疗头面部白癜风的疗效观察[J].中国误诊学杂志,2009,9(3):544-545. 被引量:4
  • 2Alkhateeb, A., Qarqaz, F., 2010. Genetic association of NALP1 with gener- alized vitiligo in Jordanian Arabs. Arch. Dermatol. Res. 302, 631-634.
  • 3Alkhateeb, A., Stetler, G.L., Old, W., Talbert, J., Uhlhorn, C., Taylor, M., Fox, A., Miller, C., Dills, D.G., Ridgway, E.C., Bennett, D.C., Fain, ER., Spritz, R.A., 2002. Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome lp31.3-p32.2. Hum. Mol. Genet. 11,661-667.
  • 4Addison, T., 1855. On the constitutional and local effects of disease of the suprarenal capsules. In: A Collection of the Published Writing of the Late Thomas Addison, M.D., Physician to Guy's Hospital, vol. 2. New Sydenham Society 1868, London, pp. 244-293. Reprinted in Med. Clas- sics (1937).
  • 5al-Fouzan, A., al-Arbash, M., Fouad, F., 1995. Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur. J. Immunogenet. 22, 209-213.
  • 6Alkhateeb, A., Fain, ER., Thody, A., Bennett, D.C., Spritz, R.A., 2003. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 16, 208-214.
  • 7Alkhateeb, A., Fain, E, Spritz, R.A., 2005. Candidate functional promoter variant in the FOXD3 melanoblast developmental regulator gene in auto- somal dominant vitiligo. J. Invest. Dermatol. 125, 388-391.
  • 8Ando, I., Chi, H.I., Nakagawa, H., Otsuka, F., 1993. Difference in clinical features and HLA antigens between familial and non-familial vitiligo of generalized type. Br. J. Dermatol. 129, 408-410.
  • 9Arcos-Burgos, M., Parodi, E., Salgar, M., Bedoya, E., Builes, J.J., Jaramillo, D., Ceballos, G., Uribe, A., Rivera, N., Rivera, D., Fonseca, I., Camargo, M., Palacio, L.G., 2002. Vitiligo: complex segregation and Liukage disequilibrium analyses with respect to microsatellite loci span- ninz the HLA. Hum. Genet. 110, 334-342.
  • 10Badri,-A.M., Todd, RM., Garioch, J.J., Gudgeon, J.E., Stewart, D.G., Goudie, R.B., 1993. An immunohistological study of cutaneous lympho- cytes in vitiligo. J. Pathol. 170, 149-155.

共引文献64

同被引文献13

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部